Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Daiichi Vows Action As $41.8m Patent Decision Favors Seagen

‘039 Claims Also Now Under Review

Executive Summary

A US jury decision in a long-running ADC patent dispute between Seagen and Daiichi Sankyo has found in favor of the US firm. But Daiichi has vowed to challenge the outcome while its motion to question the validity of the original patent on which the case is based has also just been granted, meaning the final impact remains uncertain.

You may also be interested in...



Mainstays Give And Take As Major Japan Firms Report Results

While Daiichi Sankyo reveals ambitious plan with Enhertu, Chugai shows stable growth plans with COVID-19 drugs, Astellas reacted to concerns over Xtandi’s slow growth with enthusiastic investment plan for the next potential star.

Enhertu Could Get Big Boost From Second-Line Breast Cancer Indication

An analyst forecast that about 40% of the drug’s sales could come from second-line disease, while lack of grade 4-5 interstitial lung disease events was seen as a plus.

Boost For Daiichi's Oncology Ambitions As AZ Agrees Huge $6.9bn Deal For Lead ADC Asset

AstraZeneca is paying $1.35bn upfront for global rights to a flagship Daiichi Sankyo oncology asset, in a deal potentially worth up to $6.9bn set to give a huge boost to the Japanese firm's ambitions in the sector.

Topics

Related Companies

UsernamePublicRestriction

Register

SC146209

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel